DCK and neoplasm: dCK inhibitors trigger replication stress alongside lethal DNA damage in tumor cells, and improve survival in mouse models of acute lymphoblastic leukemia (ALL) when administered alongside inhibitors of de novo dCTP synthesis, such as thymidine or triapine (117, 120).